Her clinical and research interests include various topics in breast cancer, such as angiogenesis, breast cancer in younger women, endocrine therapy, novel HER2 therapies, breast cancer vaccines, and other experimental therapeutics for breast cancer. As board certified in medical oncology, she maintains an active clinical practice of over 500 patients and has served as the PI or co-PI on over 50 clinical trials in breast cancer, including pivotal phase II and III trials that led to the approval of lapatinib for the treatment of HER2-positive breast cancer, and the recently published EMILIA trial assessing the safety and efficacy of T-DM1 in HER2-positive metastatic breast cancer. She is a past recipient of the Duke University Specialized Program of Research Excellence (SPORE) in breast cancer Young Investigator Award, the Duke Cancer Center Malek Family Award for outstanding cancer investigation, and the Joseph Greenfield Award for Research Mentorship. She serves on the national Scientific Advisory Board of the Susan G Komen for the Cure, the CALGB Correlative Science Core Committee, as well as the Steering Committee Chair for CHAMBER (Collaborations for HeAlth IMprovements in HER2+ Breast CancER). She has authored or co-authored over 60 articles or book chapters appearing in journals such as Clinical Cancer Research, Journal of Clinical Oncology, Cancer, Radiation Research, and Molecular Cancer Therapeutics.